U.S. markets closed

Seagen Inc. (SGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
212.24-0.31 (-0.15%)
At close: 04:00PM EDT
212.35 +0.11 (+0.05%)
After hours: 04:45PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close212.55
Bid212.35 x 800
Ask212.30 x 3100
Day's Range212.15 - 212.90
52 Week Range116.08 - 217.08
Avg. Volume1,252,588
Market Cap39.837B
Beta (5Y Monthly)0.48
PE Ratio (TTM)N/A
EPS (TTM)-3.89
Earnings DateOct 25, 2023 - Oct 30, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est224.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SGEN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Seagen Inc.
    Analyst Report: Seagen Inc.Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
    Fair Value
    Economic Moat
    last monthMorningstar
View more
  • Schaeffer's Investment Research

    Signal Says Buy Calls on This Biotech Stock

    SGEN's peak comes amid historically low implied volatility

  • The Wall Street Journal

    The Hedge Fund That Made a Killing Betting Against Lina Khan

    The efforts by Federal Trade Commission Chair Lina Khan to protect Main Street are inadvertently enriching some on Wall Street, generating outsize profits for Pentwater Capital Management and other large hedge funds that bet on merger deals. In both cases, the FTC’s intervention spooked investors and sent shares of the target companies swinging.

  • The Wall Street Journal

    Stocks to Watch Friday: Alibaba, Activision, Microsoft, Ford, Meta Platforms

    **↗️** [**Microsoft (MSFT)**](, [**Activision Blizzard (ATVI)**]( A modified deal by the software giant to buy the videogame publisher was [cleared by the U.